Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of Toronto

$147,200.00

Brain Cancer Treatment: innovations in delivery of stable siRNAs and chemotherapeutics

FY 2015-16

Summary
Brain cancer is largely incurable and mostly untreatable. The most common form of brain cancer, malignant gliomas, are very aggressive, resulting in patient survival of only a year after diagnosis. Present treatments for malignant gliomas largely fail because cancer cells can rapidly invade surrounding brain tissue, resulting in recurrent tumors. We found that malignant gliomas overexpress a gene, DRR, which is a primary driver of their invasiveness, yet not expressed on normal glial cells. To stop the progression and recurrence of brain cancer, we propose to target DRR. We propose to selectively knock-down DRR with siRNA and to ensure specificity to cancer cells with targeting antibodies. We will deliver the siRNA, antibodies and chemotherapeutics in tiny beads polymeric nanospheres. The drug delivery system is comprised of innovative polymer nanospheres, which penetrate the brain tumor site. Nanospheres will deliver antibodies against brain cancer, chemotherapeutics and silencing RNA to knockdown DRR. The spherical beads will degrade after releasing their payload in the cancerous tissue. This system of localized delivery is particularly compelling for invasive brain cancers where the aggressive malignant/invasive glioma cells have spread throughout the brain and are not easily removed. The long-term goal is to clinically assess the efficacy of locally-delivered targeting RNA to block invasiveness in recurrent glioblastoma and extend median progression-free and overall survival in patients. Our team has the complementary expertise required for success in the complex race to overcome brain cancer. By combining novel bioengineering strategies with innovative silencing approaches, targeting antibodies, and neurosurgery, the team will provide a superb environment for training of HQP. In collaboration with our industry, science and clinical partners, we will advance knowledge to practical application, with the ultimate goal of defeating brain cancer.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
478471-2015
Name nom
Shoichet, Molly
Department département
Chemical Engineering and Applied Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
147200
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Brain Cancer Treatment: innovations in delivery of stable siRNAs and chemotherapeutics
Keyword
NSERC
Application summary
Brain cancer is largely incurable and mostly untreatable. The most common form of brain cancer, malignant gliomas, are very aggressive, resulting in patient survival of only a year after diagnosis. Present treatments for malignant gliomas largely fail because cancer cells can rapidly invade surrounding brain tissue, resulting in recurrent tumors. We found that malignant gliomas overexpress a gene, DRR, which is a primary driver of their invasiveness, yet not expressed on normal glial cells. To stop the progression and recurrence of brain cancer, we propose to target DRR. We propose to selectively knock-down DRR with siRNA and to ensure specificity to cancer cells with targeting antibodies. We will deliver the siRNA, antibodies and chemotherapeutics in tiny beads polymeric nanospheres. The drug delivery system is comprised of innovative polymer nanospheres, which penetrate the brain tumor site. Nanospheres will deliver antibodies against brain cancer, chemotherapeutics and silencing RNA to knockdown DRR. The spherical beads will degrade after releasing their payload in the cancerous tissue. This system of localized delivery is particularly compelling for invasive brain cancers where the aggressive malignant/invasive glioma cells have spread throughout the brain and are not easily removed. The long-term goal is to clinically assess the efficacy of locally-delivered targeting RNA to block invasiveness in recurrent glioblastoma and extend median progression-free and overall survival in patients. Our team has the complementary expertise required for success in the complex race to overcome brain cancer. By combining novel bioengineering strategies with innovative silencing approaches, targeting antibodies, and neurosurgery, the team will provide a superb environment for training of HQP. In collaboration with our industry, science and clinical partners, we will advance knowledge to practical application, with the ultimate goal of defeating brain cancer.